Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Alberto Chiappori
ResearcherPublications, citations & collaboration network
Alberto Chiappori is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 257 works, 16,930 citations, an h-index of 49 and an i10-index of 105.
257
Works
16,930
Citations
49
h-index
105
i10-index
How has Alberto Chiappori's publication output changed over time?
ScholarIQpublication output · 2006–2021
Output grew100% over the shown period — from 1 works in 2006 to 2 in 2021.
1
1
1
1
1
1
1
2
1
2
2006201020132014201520162017201820192021
What are the most-cited papers on Alberto Chiappori?
ScholarIQmost cited works
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
New England Journal of Medicine. 20174,592 CitationsOPEN ACCESS
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
New England Journal of Medicine. 20182,828 CitationsOPEN ACCESS
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely, Alberto Chiappori, Howard West, Michele C. Azada, Peter N. Morcos, Ruey-min Lee, Linta Garcia, Li Yu, Frédéric Boisserie, Laura Di Laurenzio, Sophie Golding, Jotaro Sato, Shumpei Yokoyama, Tomohiro Tanaka, Sai‐Hong Ignatius Ou
The Lancet Oncology. 2014696 Citations
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou
The Lancet Oncology. 2015641 CitationsOPEN ACCESS
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Scott Antonia, Noweeda Mirza, Ingo Fricke, Alberto Chiappori, Patricia Thompson, Nicholas S. G. Williams, Gerold Bepler, George R. Simon, William E. Janssen, Ji‐Hyun Lee, Kerstin Menander, Sunil Chada, Dmitry I. Gabrilovich
Clinical Cancer Research. 2006444 CitationsOPEN ACCESS
Related on ScholarIQ
Moffitt Cancer Center
Institution
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Paper
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Paper
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Paper
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Paper
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Paper